Lysine Auxotrophy Combined with Deletion of the SecA2 Gene Results in a Safe and Highly Immunogenic Candidate Live Attenuated Vaccine for Tuberculosis

Joseph Hinchey1, Bo Y. Jeon2, Holly Alley3, Bing Chen1, Michael Goldberg1, Sheldon Morris4, William R. Jacobs Jr.1,5, Steven A. Porcelli1,6, Sunhee Lee3*

1 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America, 2 Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea, 3 Duke Human Vaccine Institute, Durham, North Carolina, United States of America, 4 Center for Biologics Evaluation, US Food and Drug Administration, Bethesda, Maryland, United States of America, 5 Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, New York, United States of America, 6 Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America

Abstract

Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a major global health problem, despite the widespread use of the M. bovis Bacille Calmette-Guerin (BCG) vaccine and the availability of drug therapies. In recent years, the high incidence of coinfection of M. tuberculosis and HIV, as well as escalating problems associated with drug resistance, has raised ominous concerns with regard to TB control. Vaccination with BCG has not proven highly effective in controlling TB, and also has been associated with increasing concerns about the potential for the vaccine to cause disseminated mycobacterial infection in HIV infected hosts. Thus, the development of an efficacious and safe TB vaccine is generally viewed as a critical achievement to control the ongoing global TB pandemic. In the current study, we have analyzed the vaccine efficacy of an attenuated M. tuberculosis strain that combines a mutation that enhances T cell priming (ΔsecA2) with a strongly attenuating lysine auxotrophy mutation (ΔlysA). The ΔsecA2 mutant was previously shown to be defective in the inhibition of apoptosis and markedly increased priming of antigen-specific CD8⁺ T cells in vivo. Similarly, the ΔsecA2ΔlysA strain retained enhanced apoptosis and augmented CD8⁺ T cell stimulatory effects, but with a noticeably improved safety profile in immunosuppressed mice. Thus, the M. tuberculosis ΔsecA2ΔlysA mutant represents a live attenuated TB vaccine strain with the potential to deliver increased protection and safety compared to standard BCG vaccination.

Introduction

Tuberculosis is a devastating disease, and despite the availability of therapeutic drugs and widespread vaccination with BCG, it remains a serious global health issue, infecting nearly a third of the world population and causing 2–3 million deaths annually [1]. Since initiating BCG vaccination in the 1920s, more than three billion people have been vaccinated with BCG [2]. However, the benefits and drawbacks of BCG have been debated since its early use. Ongoing concerns and controversies include the potential for disseminated infection by BCG in immunosuppressed hosts, loss of sensitivity to tuberculin as a diagnostic reagent, and the failure of BCG to show efficacy in the prevention of pulmonary TB in a number of trials in developing countries [3,4,5]. There have been numerous hypotheses to explain the inadequate protective effect of BCG against pulmonary TB. Factors related directly to the vaccine, such as inappropriate treatment and storage of the vaccine and strain variability have been suggested. Additionally, several deficits of a more fundamental immunological character have been proposed, such as a lack of important antigens, interaction with environmental mycobacteria, and dwindling efficacy of BCG vaccination over time [6,7]. Because various T cell subsets have been shown to participate in the immune responses against mycobacteria, the lack of an effective stimulation of the optimal blend of T cell populations, and particularly the failure to induce CD8⁺ T cells, may also explain the insufficient levels of immunity promoted by the BCG vaccine strains [7,8]. In fact, increased vaccine efficacy against tuberculosis has been observed in association with enhanced priming of CD8⁺ T cells in vivo [9,10]. As there is an urgent need for innovative protective vaccine strategies, we must identify and exploit the mechanisms that can facilitate or inhibit immunity to M. tuberculosis, while simultaneously maintaining an adequate safety profile.

In previous work, we described a novel immune-evasion strategy of M. tuberculosis by which secretion of superoxide dismutase A (SodA) inhibits the apoptotic program of infected macrophages, effectively blunting the specific CD8⁺ T-cell responses to the bacterium. In these studies, inactivation of the M. tuberculosis secA2 gene, which encodes a virulence-associated protein secretion system, enhanced the apoptosis of infected macrophages and increased priming of antigen-specific CD8⁺ T cells in vivo. Vaccination of mice and guinea pigs with the ΔsecA2
mutant significantly increased resistance to virulent *M. tuberculosis* challenge [9]. Thus, inactivation of the *secA2* gene represents a novel way to improve the immunogenicity of mycobacterial vaccines. However, in subsequent studies we observed that inactivation of *secA2* in BCG did not lead to enhanced immunogenicity (unpublished data) and the Δ*secA2* mutant retained a moderate level of virulence, making it unsuitable as a vaccine. In order to improve vaccine efficacy and safety of the Δ*secA2* mutant, we generated multiple double and triple mutants of the Δ*secA2* mutant strain via incorporation of other attenuating mutations of *M. tuberculosis*. In the current study, we have evaluated one of the double mutants, Δ*secA2ΔlysA*, and show here that this strain displays an excellent safety profile in immunocompromised SCID mice while retaining the enhanced immunogenicity of the parental Δ*secA2* mutant strain.

**Results**

**Improved attenuation of *M. tuberculosis* Δ*secA2ΔlysA* in SCID mice**

The principal advantage of incorporating auxotrophic mutations into vaccine candidates is the associated reduction in virulence. Previously, the Δ*lysA* strain of *M. tuberculosis* was shown to be unable to replicate *in vitro* in the absence of lysine supplementation of the growth medium, and to be markedly attenuated for growth *in vivo* in SCID mice, consistent with the inability of the bacteria to scavenge sufficient lysine from the intracellular environment [11,12]. Strain Δ*secA2ΔlysA* is strictly auxotrophic for lysine, and no growth of the mutant was observed in the absence of lysine supplementation. To investigate the virulence of the double mutant, SCID mice were injected intravenously with 10⁵ CFU of either wild-type *M. tuberculosis* (strain H37Rv), a Δ*secA2* mutant, or a double mutant strain Δ*secA2ΔlysA*. As expected, the Δ*secA2* single mutant of *M. tuberculosis* showed a high level of virulence in this experiment, as all animals died in less than 50 days. In contrast, a significant reduction of virulence of the Δ*secA2ΔlysA* strain was observed, as the group infected with this strain had a median survival of >300 days. In comparison, BCG infected SCID mice showed a median survival of ~150 days, and all BCG infected animals succumbed by day 165 (Figure 1). These data clearly indicated that Δ*secA2ΔlysA* was strongly attenuated and even less virulent than the BCG vaccine strain in the context of severe immunodeficiency.

**Induction of macrophage apoptosis by *M. tuberculosis* Δ*secA2ΔlysA***

The *secA2* gene encodes an accessory secretion factor required for the export of superoxide dismutase protein (SodA), an enzyme that catalyzes conversion of superoxide anions to hydrogen peroxide. In previous work we have shown that deletion of *secA2* gene results in enhanced apoptosis of infected macrophage, an effect that was reversed by the restoration of secretion of SodA through a *secA2* independent pathway [9]. To test whether the Δ*secA2ΔlysA* has retained this pro-apoptotic property, transformed human monoocyte/macrophage cells (THP-1 cells) were infected with an MOI of 10 bacilli per macrophage with H37Rv, Δ*secA2, ΔlysA*, or Δ*secA2ΔlysA*. At 72 hours following infection, quantitative assessment of apoptosis by staining for DNA strand breakage (TUNEL) showed that both Δ*secA2* and Δ*secA2ΔlysA* demonstrated high levels of apoptosis, whereas WT *M. tuberculosis* and the single mutant auxotrophic Δ*lysA* did not (Figure 2). These results indicated that the defect in apoptosis inhibition resulting from the loss of Δ*secA2* was retained in the Δ*secA2ΔlysA* double mutant.

![Figure 1. Survival of immunocompromised mice after infection with virulent *M. tuberculosis*, Δ*secA2*, Δ*secA2ΔlysA*, or BCG. SCID mice were infected intravenously with 10⁵ CFUs of virulent *M. tuberculosis* (H37Rv), Δ*secA2*, BCG Pasteur, or Δ*secA2ΔlysA*. Mice were followed for survival, or were sacrificed humanely when moribund.](doi:10.1371/journal.pone.0015857.g001)

**Augmented CD8⁺ T cell priming following immunization with Δ*secA2ΔlysA***

As illustrated in earlier work, an important consequence of blocking apoptosis is an effective reduction of the priming of CD8⁺ T cell response to *M. tuberculosis*. *M. tuberculosis* antigens are produced within a phagosomal compartment which is sequestered from the classical cytoplasmic pathway of antigen processing. As with other vacuolar pathogens, such as *Salmonella*, display of these antigens on MHC class I molecules likely occurs by the uptake and presentation of apoptotic material by bystander dendritic cells (DC) [13]. Consistent with this idea, we have previously shown that mice vaccinated with the Δ*secA2* mutant strain exhibited a marked enhancement of CD8⁺ T cell priming. To test whether the Δ*secA2ΔlysA* mutant strain retained the enhanced immunogenicity observed in the parental Δ*secA2* strain, we used a CD8⁺ T cell adoptive transfer strategy similar to that described previously [9]. Recipient mice injected with low numbers (5 × 10⁵) of OT-I T cells were vaccinated subcutaneously with recombinant *M. tuberculosis* strains expressing the 19-kDa lipoprotein-SIINFEKL fusion protein. This experimental design enabled accurate quantification of antigen-specific CD8⁺ T cells by tetramer staining in mice vaccinated with H37Rv-OVA, Δ*secA2-OVA, ΔlysA-OVA*, and Δ*secA2ΔlysA-OVA*. As anticipated, mice vaccinated with H37Rv-OVA and ΔlysA-OVA showed little detectable expansion of transferred T cells, while the pro-apoptotic strains, Δ*secA2-OVA*, and Δ*secA2ΔlysA-OVA* induced significant expansion of antigen specific CD8⁺ T cells (Figure 3A). We also measured expression of CD62 ligand (CD62L) and CD44 on tetramer⁺ cells to distinguish between naive (CD44⁺CD62L⁺), central memory (CD44⁺CD62L⁵⁺), and effector memory cells (CD44⁺CD62L²⁺). Our results showed enhanced expansion of both subsets in mutant strains deficient in *secA2* (Figure 3B, C). In addition, we were able to demonstrate a measurable induction of endogenous CD8⁺ T cells in mice vaccinated intravenously with Δ*secA2-OVA* and Δ*secA2ΔlysA-OVA*, with little detectable expansion of tetramer positive cells in mice vaccinated with H37Rv-OVA and Δ*lysA*-OVA (Figure 4).
Protective immunity against virulent *M. tuberculosis* challenge following vaccination with ΔsecA2ΔlysA

As discussed above, although ΔlysA has a compelling safety profile in immunocompromised animals, and performs much better than BCG in our studies conducted in SCID mice, its poor growth in vivo comes at the cost of weaker immunogenicity. To determine whether the enhanced T cell priming observed with ΔsecA2ΔlysA correlated with improved performance as a live vaccine strain, we conducted immunization and challenge studies designed to evaluate potential vaccine efficacy of the double mutant. C57BL/6 mice that were either naive or immunized 8 weeks earlier by subcutaneous immunization with live ΔsecA2ΔlysA, ΔsecA2 or BCG (Pasteur strain) were challenged by low-dose aerosol infection with virulent *M. tuberculosis* (Erdman). In naive mice, substantial growth in the lungs and dissemination to spleens were detected within 1 month of challenge. In contrast, vaccination with ΔsecA2ΔlysA, ΔsecA2 and BCG considerably reduced *M. tuberculosis* bacillary loads in both lungs and spleens of aerosol-challenged mice as compared with naive controls (Figure 5A).

Immunization with ΔsecA2 and ΔsecA2ΔlysA also showed a more prolonged effect on control of *M. tuberculosis* infection, which was still apparent 3 months after challenge. More importantly, the protection evoked by ΔsecA2ΔlysA immunization was significantly greater than that obtained with BCG vaccination, as measured by bacterial burden in both the lung and spleen at 3 months post challenge (0.66-log reduction in lungs of ΔsecA2ΔlysA versus BCG vaccinated mice; *P*<0.001, 0.68-log reduction in spleens ΔsecA2-ΔlysA versus BCG vaccinated mice; *P*<0.01). Interestingly, ΔsecA2ΔlysA vaccinated mice also showed significantly lower lung bacillary loads than mice vaccinated with ΔsecA2 (0.35-log reduction in lungs of ΔsecA2ΔlysA versus ΔsecA2 vaccinated mice; *P*<0.05) (Figure 5A), an effect that may relate to the enhanced stability of memory cells in response to non-persistent live vaccines [14,15,16]. The one month time point represents the peak bacillary burden and the 3 month time point represents the set point of the bacillary burden in the chronic phase of infection. Histopathological examination of the lungs from mice immunized with BCG, ΔsecA2, or ΔsecA2ΔlysA showed relatively mild inflammation with less severe spreading lung lesions, less extensive granulomatous pneumonia, and reduced consolidation compared with naive mice (Figure 5B).

**Discussion**

In recent years a number of attenuated strains of *M. tuberculosis*, many constructed through the engineered deleting of genes important for growth in vivo, have been shown to confer protection against challenge with virulent *M. tuberculosis* [17,18]. The appeal of auxotrophic mutant strains, from the standpoint of vaccine development, relates to their marked growth attenuation in vivo and exceptional safety profile in immunocompromised animals. However, a significant drawback of many of these strains is poor immunogenicity in immunocompetent animals, which appears to be a function of reduced growth and decreased antigen load. Consistent with this view, the ΔlysA mutant strain, while shown to be profoundly attenuated in SCID mice, required multiple rounds of immunization to achieve levels of protection comparable to BCG in immunocompetent mice [19]. In contrast, we have shown in the current study that a single immunization with the ΔsecA2ΔlysA strain conferred markedly enhanced protection from challenge with virulent *M. tuberculosis* when compared to BCG. A similar result was previously observed for the parental ΔsecA2 strain, which exhibited enhanced CD8+ T cell priming when compared with wild-type *M. tuberculosis*, while conferring enhanced protection to vaccinated mice and guinea pigs compared to BCG. Enhanced immunogenicity of ΔsecA2 correlated with the loss of apoptosis inhibition by the mutant strain. This proapoptotic phenotype was preserved in the ΔsecA2ΔlysA strain, along with the enhanced CD8+ T cell stimulating effect. In the present study, we confirmed our previous finding that ΔsecA2 conferred enhanced protection against virulent challenge when compared with BCG, and demonstrated that vaccination with the ΔsecA2ΔlysA double mutant strain also gave protection that was significantly better than that achieved with BCG. In fact, ΔsecA2ΔlysA vaccination led to a significantly greater...
reduction in CFU in the lungs of immunocompetent mice at 3 months, when compared with the parental ΔsecA2 strain.

The explanation for this augmented protective efficacy of ΔsecA2ΔlysA vaccination may relate to the inability this strain to persist in vivo, leading to more rapid antigen clearance after T cell priming and more stable memory T cell populations [20]. This is a substantial difference from the parental ΔsecA2 single mutant, which is known to be only moderately attenuated for growth in mice and most likely persists at least at low levels for many weeks and perhaps permanently [21]. Research on T cell responses to viral pathogens including LCMV, Hepatitis C, and SIV, suggests that the persistence of antigen stimulation associated with chronic infection can lead to the functional impairment or ablation of effector and memory CD8+ T cell responses. In this model, too little antigen leads to suboptimal responses, whereas an over-abundance or prolonged expression of antigen leads to a suboptimal reservoir of memory T cells [22,23,24,25]. Through the pairing of the augmented CD8+ T cell priming properties of the ΔsecA2 mutation with the restrained growth imparted by ΔlysA, we may have achieved a more favorable formulation to generate robust, yet stable, memory responses in vaccinated animals.

A salient advantage of the auxotrophic double mutant, illustrated here, is its marked attenuation in immunocompromised mice. Due to the high incidence of HIV-infection in regions where TB is endemic, safety of immunocompromised animal models has become an important consideration for experimental vaccines. Even BCG, widely regarded as a safe vaccine, has been shown to progress to disease in a significant subpopulation of HIV infected individuals. In a study of BCG vaccinated HIV-positive children conducted in 2003, 10% of mycobacterial disease was attributed to BCG [26]. HIV infection leads to a disproportionate loss of CD4+ T cells, which in experimental models have been shown to be essential for controlling infection with BCG [27]. Although CD4+ T cells are critical for protective anti-TB protective immunity [28], CD8+ T cells have been shown to play an important role in the control of TB, particularly in CD4-deficient mice [5,6,29]. Thus, the ΔsecA2ΔlysA strain, with an improved safety profile and augmented CD8+ T cell immunogenicity, may serve as an effective substitute for BCG in the HIV infected population.

Consistent with results from our previous work characterizing the immunogenicity of ΔsecA2, the mechanisms underlying the augmented vaccine properties of ΔsecA2ΔlysA appear to stem, at
least in part, from a loss of apoptosis inhibition, enhanced CD8\(^+\) T cell priming and memory T cell generation. In addition, by coupling the moderately attenuating \(\Delta secA2\) mutation with \(\Delta lysA\) we were not only able to achieve a superior safety profile, but also significantly improved control of infection relative to the parental strain. The rational design of novel, live attenuated vaccines for

**Figure 4.** Enhanced priming of endogenous SIINFEKL-specific CD8\(^+\) T cells following immunization with \(\Delta secA2\Delta lysA\). The frequencies of SIINFEKL-specific CD8\(^+\) T cells in spleens from mice infected with the indicated strains of \(M.\) tuberculosis were determined. The percentage of CD8\(^+\) cells staining with SIINFEKL-loaded H-2K\(^b\) tetramers and representative FACS plots are shown for cohorts of four mice that were analyzed 7 days after intravenous infection. Asterisks indicate statistical significance compared to Rv-ova (*, p < 0.05; one-way ANOVA test).

doi:10.1371/journal.pone.0015857.g004

**Figure 5.** Protective immunity against virulent \(M.\) tuberculosis challenge in mice following vaccination with \(\Delta secA2\Delta lysA\). (A) C57BL/6 mice were vaccinated subcutaneously with saline (naïve) or with \(1 \times 10^6\) BCG, \(M.\) tuberculosis \(\Delta secA2\) or \(\Delta secA2\Delta lysA\). All mice were challenged by aerosol 2 months later with 50–100 CFU of virulent \(M.\) tuberculosis (Erdman strain). Graphs show means and standard errors of colony forming units (CFU) of \(M.\) tuberculosis in lungs and spleens at 1 and 3 months after challenge for groups of five mice. Asterisks indicate statistical significance compared to unvaccinated group or between bracketed groups (*, p < 0.05; **, p < 0.01; \(\Phi\), p < 0.001; two-way ANOVA). (B) Lungs of mice vaccinated and challenged with virulent \(M.\) tuberculosis as in (A) were examined histologically at 1 month and 3 months post-challenge. More severe spreading lung lesions with extensive granulomatous pneumonia and consolidation were observed in unvaccinated mice as compared to mice vaccinated with BCG, \(\Delta secA2\), or \(\Delta secA2\Delta lysA\).

doi:10.1371/journal.pone.0015857.g005
tuberculosis depends on integrated disruption of multiple pathogen virulence strategies. This study clearly demonstrates a proof of this principle by combining secA2 with a second mutation that interferes with virulence of M. tuberculosis, thus generating a novel attenuated candidate mycobacterial vaccine strain with significantly improved safety and efficacy.

**Materials and Methods**

**Bacterial strains and growth media**

Virulent M. tuberculosis strains H37Rv (obtained from Trudeau Institute), Erdman, M. tuberculosis secA2 mutant (mc²3112), and AlysA have been described previously [30]. M. tuberculosis strains were grown on Middlebrook 7H9 broth or 7H10 agar containing 10% (vol/vol) oleic acid–albumin–dextrose–catalase (OADC; BD Diagnostics-Diagnostic Systems), 0.5% glycerol, and 0.05% (vol/vol) Tween-80. For AlysA and secA2lysA, the culture medium was supplemented with L-lysine (80 μg/ml). The E. coli strain DH5α was used for cloning purposes and grown on Luria-Bertani agar or broth (Fisher Scientific) at 37°C. Ampicillin (50 μg/ml), hygromycin (50 μg/ml for mycobacterial selection or 150 μg/ml for E. coli), and kanamycin (20 μg/ml for mycobacterial selection or 40 μg/ml for E. coli) were used to select for recombinant strains.

**Construction of recombinant mycobacterial strains**

The double mutant strain secA2lysA was constructed using specialized transduction to disrupt the chromosomal copy of the flyA gene of an unmarked secA2 clone, as described [30]. To generate OVA expressing strains of wild type M. tuberculosis (H37Rv-OVA) or of mutants (secA2-OVA, AlysA-OVA, and secA2lysA-OVA), the wild type and mutant strains were transformed with the plasmid p19OVA which encodes the M. tuberculosis 19kD lipoprotein fused at the C-terminus with the sequence for ovalbumin that includes the MHC class I presented epitope SIINFEKL [9]. Transformations of M. tuberculosis were performed according to a published protocol [31].

**Apoptosis studies in THP-1 cells**

THP-1 cells (ATCC) were grown in RPMI-1640 (Gibco BRL; Invitrogen) supplemented with 10% FBS, 1% HEPES, 1% nonessential amino acids and essential amino acids. THP-1 cells were treated with 8 ng/ml PMA (Sigma-Aldrich) in order to induce differentiation into macrophage-like cells. Differentiated THP-1 cells were plated in 6-well plates at 2 × 10⁶ cells per well and allowed to adhere overnight. Dispersed bacilli were incubated with cells for 3 hours using a multiplicity of infection (MOI) of 10 bacteria to 1 THP-1 cell. The cells were then washed twice with PBS and incubated at 37°C in a 5% CO₂ incubator for 72 hours. The presence of apoptotic cells in the cell cultures was analyzed with In Situ Cell Death Detection Kit, Fluorescence (Roche Diagnostics), following the manufacturer’s instructions.

**T cell activation studies**

C57BL/6 mice received 5 × 10⁵ splenocytes from OVA-specific TCR transgenic OT-1 mice (Taconic/National Institute of Allergy and Infectious Diseases [NIAID]) intravenously, and then infected subcutaneously 24 hours later with 1 × 10⁶ CFU H37Rv-OVA, secA2-OVA, AlysA-OVA, or secA2lysA-OVA. At 5 weeks post immunization, splenocytes were isolated and stained with PE-labeled peptide-loaded (SIINFEKL) H-2Kb tetramers in combination with antibodies specific to Thy1.2, CD44, CD62L and B220 (all antibodies were purchased from BD Biosciences). Percentages of lymphocytes stained with tetramer and expressing markers consistent with central (CD44⁺CD62L⁺), or effector (CD44⁺CD62L⁻) memory cells were determined by flow cytometry. For detection of endogenous OVA responsive T cells, mice were infected intravenously with 1 × 10⁵ CFU H37Rv-OVA, secA2-OVA, AlysA-OVA, or secA2lysA-OVA. After 7 days splenocytes were isolated and stained with PE-labeled peptide-loaded (SIINFEKL) H-2Kb tetramers in combination with antibodies specific to CD8.

**Vaccination and challenge studies**

All animal studies were approved by the institutional animal care and use committees of the Albert Einstein College of Medicine (A3312-01), the Center for Biologies Evaluation and Research, and the Duke University (A071-10-03). C57BL/6 mice were vaccinated subcutaneously with 1 × 10⁶ CFU of M. tuberculosis secA2, secA2lysA, or M. bovis BCG-Pasteur as described previously [32]. Aerogenic challenge was performed 2 months later using a Glas-Col inhalation chamber to deliver 50–100 CFU per animal of M. tuberculosis Erdman strain. Mice were sacrificed at 1 and 3 months after challenge. Lungs and spleens of individual mice were aseptically removed and homogenized separately in 5 ml normal saline plus 0.05% Tween-80 using a Seward Stomacher 80 blender (Tekmar). The homogenates were diluted serially and plated on Middlebrook 7H10 agar. Lung tissues were processed for histopathology using standard paraffin fixation, sectioning, and H&E staining. In the survival study, animals infected with M. tuberculosis Erdman were observed daily until they died or became moribund and were euthanized.

**Statistics**

Two-way ANOVA with Bonferroni’s post test and one-way ANOVA with the Tukey post test were used for analyses using GraphPad Prism version 5 for Windows (GraphPad; [www.graphpad.com]). P values of less than 0.05 were considered significant.

**Acknowledgments**

TB research by SL was performed in the NIAID Regional Biosafety Laboratory at Duke under the direction of Dr. Richard Frothingham. Flow cytometry by SL was performed in the Duke Human Vaccine Institute Research Flow Cytometry Shared Resource Facility (Durham, NC) under the direction of Dr. John F. Whitesides. Peptide-loaded H-2Kb tetramers were obtained from the tetramer core facility at the Memorial Sloan-Kettering Cancer Center. We thank Mei Chen, Weijun Liu, and Kristina Riehe for their technical help.

**Author Contributions**

Conceived and designed the experiments: JH SM WRJ SAP SL. Performed the experiments: JH BYJ BC HA MG SL. Analyzed the data: JH SL. Wrote the paper: JH SAP SL. Contributed to the conception and design, and acquisition of data: SD.

**References**

1. Maher D, Ravignone M (2005) Global epidemiology of tuberculosis. Clin Chest Med 26: 167–182, v.
2. Kaufmann SH, Hussey G J Lambert PH New vaccines for tuberculosis. Lancet 375: 2110–2119.
3. Villarreal-Ramos B (2009) Towards improved understanding of protective mechanisms induced by the BCG vaccine. Expert Rev Vaccines 8: 1351–1354.
4. Andersen P (2007) Tuberculosis vaccines - an update. Nat Rev Microbiol 5: 484–487.
5. Behar SM, Woodworth JS, Wu Y (2007) Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev Vaccines 6: 441–456.

6. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC (2009) Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 21: 351–358.

7. Sereika YA, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4: 469–476.

8. Andersen P, Doherty TM (2005) The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656–662.

9. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, et al. (2007) Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117: 2279–2288.

10. Grode L, Seder P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472–2479.

11. Consaul SA, Jacobs WR, Jr., Pavelka MS, Jr. (2003) Extragenic suppression of the requirement for diaminopimelate in diaminopimelate auxotrophs of Mycobacterium smegmatis. FEMS Microbiol Lett 225: 131–135.

12. Pavelka MS, Jr., Jacobs WR, Jr. (1996) Biosynthesis of diaminopimelate, the precursor of lysine and a component of peptidoglycan, is an essential function of Mycobacterium smegmatis. J Bacteriol 178: 6496–6507.

13. Winau F, Hegasy G, Kaufmann SH, Schaible UE (2005) No life without death–apoptosis as prerequisite for T cell activation. Apoptosis 10: 707–715.

14. Wherry EJ, Ahmed R (2004) Memory CD8 T-cell differentiation during viral infection. J Virol 78: 5535–5545.

15. Serbina NV, Flynn JL (2001) CD8 (T) cells participate in the memory immune response to Mycobacterium tuberculosis. Infect Immun 69: 4320–4328.

16. Serbinova E, Flynn JL (2003) CD8+ effector and memory T cell generation. Nat Immunol 4: 835–842.

17. Sambandamurthy VK, Jacobs WR, Jr. (2002) Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7: 955–961.

18. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR, Jr. (2003) Survival perspectives from the world’s most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 4: 949–955.

19. Pavelka MS, Jr., Chen B, Kelley CL, Collins FM, Jacobs Jr. WR, Jr. (2003) Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun 71: 4190–4192.

20. Ha SJ, West EE, Araki K, Smith KA, Ahmed R (2006) Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 223: 317–333.

21. Braunstein M, Brown AM, Kurtz S, Jacobs Jr. WR, Jr. (2001) Two nonredundant SecA homologues function in mycobacteria. J Bacteriol 183: 6979–6980.

22. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911–4927.

23. Vogel TU, Allen TM, Altman JD, Watkins DI (2001) Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection. J Virol 75: 2458–2461.

24. Wedemeyer H, He XS, Nascimbene M, Davis AR, Greenberg HB, et al. (2002) Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169: 3447–3454.

25. Fuller MJ, Zajac AJ (2003) Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 170: 477–486.

26. Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, et al. (2003) Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37: 1226–1233.

27. Ludel CH, Daugelat S, Kaufmann SH (1995) Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 25: 377–384.

28. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93–129.

29. Serbina NV, Flynn JL (2003) CD8 (+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect Immun 69: 4320–4328.

30. Bardarov S, Bardarov Jr. S, Jr., Pavelka Jr. MS, Jr., Sambandamurthy V, Larsen M, et al. (2002) Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148: 3007–3017.

31. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456–460.

32. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8: 1171–1174.